5 Stocks With 3x-5x Returns This Year

2. Erasca Inc. (NASDAQ:ERAS)

Erasca has seen its share prices soar by 390 percent year-to-date, as investors sought to increase their exposure in the company amid developments on its treatment candidate for solid tumors.

Earlier in the year, Erasca Inc. (NASDAQ:ERAS) expanded its worldwide rights to develop and commercialize its treatment candidate, ERAS-0015—which has a best-in-class potential—to China, Hong Kong, and Macau, sparking revenue growth opportunities in the said areas.

In addition, it inked a collaboration and supply agreement with Tango Therapeutics Inc. to evaluate the efficacy of ERAS-0015 when combined with the latter’s PRMT5 inhibitor, vopimetostat (TNG462).

The combination represents a promising opportunity to redefine the standard of care in patients with MTAP-deleted RAS-mutant (MTAPdel RASm) cancers, where treatment options remain limited, Erasca Inc. (NASDAQ:ERAS) said.

The company is targeting to report the results of its clinical trial for ERAS-0015 in the first half of the year, as well as for its pan-KRAS inhibitor, ERAS-4001, in the second half of the year.

ERAS-4001 is an oral, highly potent, and selective inhibitor targeting solid tumors with KRAS mutations.

Last year, Erasca Inc. (NASDAQ:ERAS) narrowed its net loss by 22.9 percent to $124.5 million from $161.6 million in 2024. Total operating expenses declined by 21 percent to $140.9 million from $179.5 million year-on-year.